Research Article

Serological Survey of Foot-and-Mouth Disease Virus in Buffaloes (Syncerus caffer) in Zambia

T. K. W. Sikombe, 1,2 A. S. Mweene, 1 John Muma, 1 C. Kasanga, 3 Y. Sinkala, 1, 4 F. Banda, 2
M. Mulumba, 5 E. M. Fana, 6 C. Mundia, 7 and M. Simuunza 1

1 Department of Disease Control, School of Veterinary Medicine, University of Zambia, P.O. Box 32379, Lusaka, Zambia
2 Central Veterinary Research Institute, P.O. Box 33980, Lusaka, Zambia
3 Faculty of Veterinary Medicine, Sokoine University of Agriculture, P.O. Box 3021, Morogoro, Tanzania
4 National Livestock Epidemiology and Information Centre, P.O. Box 30041, Lusaka, Zambia
5 Southern African Development Community Secretariat, SADC House, Plot No. 54385, Central Business District,
Private Bag 0095, Gaborone, Botswana
6 Botswana Vaccine Institute, Private Bag 0031, Gaborone, Botswana
7 Department of Veterinary Services, Southern African Development Community, Trans-Boundary Animal Disease Section,
Ministry of Agriculture and Livestock, P.O. Box 50060, Lusaka, Zambia

Correspondence should be addressed to T. K. W. Sikombe; tingiyasikombe@yahoo.com

Received 7 April 2015; Revised 27 June 2015; Accepted 16 July 2015

Academic Editor: Timm C. Harder

Copyright © 2015 T. K. W. Sikombe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A study was conducted to determine the serotypes of foot-and-mouth disease viruses (FMDV) circulating in African buffaloes (Syncerus caffer) from selected areas in Zambia. Sera and probang samples were collected between 2011 and 2012 and analysed for presence of antibodies against FMDV while probang samples were used to isolate the FMDV by observing cytopathic effect (CPE). Samples with CPE were further analysed using antigen ELISA. High FMD seroprevalence was observed and antibodies to all the three Southern African Territories (SAT) serotypes were detected in four study areas represented as follows: SAT2 was 72.7 percent; SAT1 was 62.6 percent; and SAT3 was 26.2 percent. Mixed infections accounted for 68.6 percent of those that were tested positive. For probang samples, CPE were observed in three of the samples, while the antigen ELISA results showed positivity and for SAT1 (n = 1) and SAT2 (n = 2). It is concluded that FMDV is highly prevalent in Zambian buffaloes which could play an important role in the epidemiology of the disease. Therefore livestock reared at interface with the game parks should be included in all routine FMDV vaccination programmes.

1. Introduction

Foot-and-mouth disease (FMD) is a highly infectious viral disease of domestic and wild cloven hoofed animals [1–3]. The disease is caused by the foot-and-mouth disease virus (FMDV) of the genus Aphthovirus belonging to the family Picornaviridae. The first report of FMD in Zambia dated from 1933 in Barotseland (now Western Province). Typing of the virus from Zambian FMD outbreaks began in 1948 when the Southern African Territories (SAT) immunological types of FMD virus were recognised [4]. Currently, FMD is endemic in some parts of Northern and Muchinga Provinces along areas bordering Tanzania and in southern border areas between Zambia and Zimbabwe, Botswana and Namibia and along the Kafue and Zambezi flood plains which are also bordered by parts of Kafue National Park. These areas are densely populated with domestic and game animals which are usually in contact for most part of the year. The FMD scenario in Zambia is complicated by the presence of a stable wildlife reservoir, the African buffaloes “Syncerus caffer,” and traditional practice of transhumant grazing, where cattle farmers trek their animals to wildlife sanctuaries in search of water and pasture [5–7] and where there are several viruses with high sequence diversity due to the nature of
FMDV [8, 9]. African buffaloes are known to be carriers of FMDV and as such contact exposes cattle to the risk of being infected. It has also been reported that FMD may circulate undetected in vaccinated cattle herds and in some indigenous breeds reared in areas where FMD is endemic [10].

Zambia has continued to experience isolated outbreaks of FMD such as those that occurred in Namwala in 2005 [11] and in 2008 [12]; Itezhi-Tezhi in 2006 [13] and in 2008 [12]; and Monze and Mazabuka in 2007 [14] and in 2008 [12]. These outbreaks were considered as reoccurrences of the 2004 SAT1 outbreak (Yona Sinkala, personal communications, 2012). In December 2007, SAT2 FMDV outbreaks occurred in Seshenke district in Western Province and Kazungula district of Southern Province [12]. The disease spilled over in 2008 and spread to Senanga, Mongu, Shang’ombo, and Kalabo districts of Western Province [12]. In 2009, there was an outbreak in Mbala, Northern Province, where SAT1 was isolated [15]. In 2010, there was another outbreak in Mbala district, which spread to Chinsali district, and serotype O was isolated [16]. In 2012, Mbala district and Kazungula/Livingstone experienced further outbreaks, where SAT2 and SAT1 were isolated, respectively [17, 18].

FMD is endemic in Zambia and continues to impact negatively on the livestock industry development. Little understanding of the epidemiology of FMDV has led to the continuous occurrences of the disease in Zambia. Cattle movement and trade restrictions resulting from occurrence of this disease have led to severe negative impacts for pastoral and agropastoral families who are most reliant on livestock products for food and economic security [19]. In addition trade restrictions imposed by other countries mean that the country is not able to participate fully in trade of livestock and its byproducts regionally and internationally.

FMD vaccination campaigns are conducted biannually in most parts of Zambia, where the disease is endemic. Although vaccination offers a potential solution, there are questions surrounding the efficacy of the vaccines used since there are many different serotypes (SAT1, SAT2, and SAT3, type O and type A) of FMD viruses reported to be circulating in Zambia [4, 20]. Due to this the vaccines used may not sufficiently match the field strains circulating that often even their homologous potency is unknown and the cold chain crucial for the success of any FMD vaccination is difficult to maintain. Trivalent vaccines (SAT1, SAT2, and SAT3) were used annually in Southern, Central, and Western Provinces of Zambia before 2006. After 2006, bivalent vaccines (SAT1 and SAT2) were used in Southern, Central, and Western Provinces of Zambia where our study was based, while bivalent vaccines (SAT1 and SAT2 or SAT1 and type A or SAT1 and type O) have been used in Northern and Muchinga Provinces of Zambia, bordering Tanzania; unfortunately this area was not covered by our study. This study therefore was conducted to determine the infection status and FMD virus (FMDV) serotypes circulating in buffaloes in Zambia. Thus the epidemiological situation of FMDV will be discussed.

2. Material and Methods

2.1. Study Area. The study was carried out in areas located in National Parks (NP) and Game Management Areas (GMA) in Zambia (Figure 1). Five locations were selected for this study which included Mosi-oa-tunya (S: 17°52.370′; E: 025°50053′), Sichifulo (S: 16°49.470′; E: 025°29.482′), Lower Zambezi (S: 15°38.384′; E: 029°36.756′), Lundazi (S: 12°17.157′; E: 033°10.836′), and Sioma (S: 17°08.890′; E: 23°65.3367′). These areas were purposively selected because of the presence of interactions between cattle and wildlife resulting from the transhumant cattle husbandry practice where traditional cattle farmers bring their livestock for grazing into wildlife habitats in search of greener pastures and water. These areas are among the major ecosystems of buffaloes in Zambia. Luangwa National Park has the highest density of buffaloes in Zambia (Chuma Simukonda, personal communications, 2011). However, cattle-wildlife interactions are more pronounced in the Kafue flats where FMD outbreaks occur frequently [5].

2.2. Study Design. This was a cross-sectional survey carried out from 2011 to 2012 under a special research licence provided by the Zambia Wildlife Authority (ZAWA). It was part of a wider survey undertaken by the Southern African Development Community Transboundary Animal Diseases (SADC TADs) disease surveillance programme. The licence approved sampling of 25 buffaloes from each of the five study areas (Mosi-oa-tunya, Sichifulo, Lower Zambezi, Lundazi, and Sioma) (DVLD/3/22/1: National Parks, Game Reserves and Wildlife). Therefore, we targeted to sample 125 animals.

2.3. Sample Collection. Targeted animals were buffaloes aged between six months and six years. This was done to exclude young animals that still had maternal antibodies and those older animals that were no longer prone to infection. The age range of the buffalo was determined by the protrusions of the horns based on aerial view first and before sampling the age range was determined by checking the horns and dentition [21]. Animals were first immobilised through remotely injecting chemical anaesthetic agent, etorphine hydrochloride (M99, Immobilon; Novartis, South Africa).
Veterinary Medicine International

From the immobilised animals, about 8 mL of blood was collected from all the 99 buffaloes through the jugular vein puncture using a sterile vacutainer needle into plain vacutainer tubes. The blood was left to clot overnight at room temperature and then centrifuged at 2500 rpm for 5 minutes to separate the serum. Sera were stored at −20°C until needed for laboratory analysis.

Probang samples were collected from 49 buffaloes using probang cups as recommended in the OIE Terrestrial Manual [22]. The collected probang samples were mixed with FMDV transport media (composed of 0.08 M phosphate buffer containing 0.01% bovine serum albumin, 0.002% phenol red, 1000 units/mL penicillin, 100 units/mL mycostatin, 100 units neomycin, and 50 units/mL polymyxin and adjusted to pH 7.2) [22] in the ratio of 1:3 in a conical tube after which the mixture was transferred into a cryotube. The cryotube containing probang sample was then put into a liquid nitrogen tank. Probang cups were disinfected using liquid nitrogen or in the freezer at −20°C until needed.

The collected probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

The probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

The probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

The probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

The probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

The probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

The probang samples were treated and passaged in RM monolayer cell cultures and then examined for cytopathic effect (CPE). If no CPE was detected after 48 hours, the cells were frozen and thawed, used to inoculate fresh cell cultures, and examined for CPE for another 48 hours. Some field viruses may require several passages before they become adapted [22]. In antigen ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

2.4. Sample Analysis. Detection of antibodies against FMDV in sera was done at Central Veterinary Research Institute (CVRI) in Lusaka and Botswana Vaccine Institute (BVI) using the liquid phase blocking ELISA (Institute for Animal Health, Pirbright Laboratory, UK) technique for the detection of antibodies against FMDV in sera as described by [23] and the PrioCHECK FMDV-NS test (Prionics Lelystad B.V., Netherlands), a blocking ELISA that can measure antibody level to 3ABC nonstructural proteins [24].

2.5. Data Analysis. Data was stored in basic Excel format for easy handling and storage. The data was transferred to SPSS 16.0 for statistical analysis. Proportion of positive sera, with the 95% confidence intervals (CI) on both LPBE and PrioCHECK FMDV-NS test, were estimated. The associations between categorical variables and the ELISA tests results were evaluated using Fisher’s exact test, while Kappa test was used to evaluate the agreement between the LPBE and PrioCHECK FMDV-NS test cross-tabulation results. p values <0.05 were considered statistically significant.

3. Results

3.1. Serology Results

3.1.1. LPBE Test. A total of 99 serum samples were tested and the results are shown in Table 1. The overall FMD prevalence based on LPBE SAT serotype results was 92.9 percent (95% CI = 87.8–98.0). The SAT1 prevalence was highest in Lower Zambezi and Lundazi (88.0%, 95% CI = 68.8–97.4), while no animals tested positive to SAT1 serotypes in Sioma National Park. There was a significant difference in SAT1 prevalence among the sampling sites (p = 0.001). SAT2 prevalence was highest in Lundazi where all animals tested positive (100%, 95% CI = 83.3–100), with no animals testing positive to Sioma. There was a significant difference in prevalence among the sampling sites (p = 0.001). SAT3 prevalence was highest in Sichifulo (50%, 95% CI = 27.2–72.8), with no animals testing positive to Sioma. There was a significant difference in SAT3 prevalence among the sampling sites (p = 0.001). All the buffaloes sampled (100%, 95% CI = 83.3–100) from Lower Zambezi and Lundazi were positive to antibodies against FMDV on the LPBE test and all those from Lundazi were positive to at least (100%, 95% CI = 83.3–100) two serotypes.

The few calves (age ranging from six months to eight months) that were sampled were all from Sioma and were all negative for FMDV SAT antibodies. The highest prevalence according to age range was in the 1-2-year category of which all were positive for antibodies against FMDV. In the 3-4-year age category, 93.1% were positive for antibodies against FMDV, while, in the 5-6-year age category, all were positive for antibodies against FMDV, while, in the 6-7-year age category, all were positive for antibodies against FMDV. In the 7-8-year age category, all were positive for antibodies against FMDV.

3.1.2. PrioCHECK FMDV-NS Test. A total of 99 serum samples were tested on the assay. FMD overall prevalence, based on the PrioCHECK FMDV-NS ELISA test which detects antibodies to nonstructural viral proteins, was high, 84.8% (95% CI = 77.2–91.5). The prevalence according to area of sampling was as follows: Lower Zambezi (n = 25), 96% (95% CI = 88.3–103.7); Lundazi (n = 25), 100% (95% CI = 100–100); Mosi-oa-tunya (n = 25), 80% (95% CI = 64.3–95.7); and Sichifulo (n = 20), 75% (95% CI = 56.0–94.0). The few calves (age ranging from six months to eight months) that were sampled were all from Sioma and were all negative to SAT2 serotypes.
Table 1: Seroprevalence of FMDV by LPBE SAT.

| Study area          | Number tested | SAT1 %        | SAT2 %        | SAT3 %        | Overall prevalence % | Mixed infection % |
|---------------------|---------------|---------------|---------------|---------------|----------------------|------------------|
| Lower Zambezi       | 25            | 88.0 (68.8–97.4) | 84.0 (63.9–95.5) | 8.0 (0.98–26) | 100.0 (83.3–100)    | 84.0 (63.9–95.5) |
| Lundazi             | 25            | 88.0 (68.8–97.4) | 100.0 (83.3–100) | 12.0 (2.5–31.2) | 100.0 (83.3–100)    | 100.0 (83.3–100) |
| Mosi-oa-tunya       | 25            | 32.0 (14.9–53.5) | 76.0 (59.3–92.7) | 44.0 (24.4–65.1) | 92.0 (74.0–99.9)    | 60.0 (38.7–78.9) |
| Sichifulo           | 20            | 45.0 (23.1–68.3) | 35.0 (15.4–59.2) | 50.0 (27.2–72.8) | 95.0 (75.1–99.9)    | 35.0 (15.4–59.2) |
| Sioma               | 4             | 0             | 0             | 0             | 0                    | 0                |

Table 2: Prevalence of LPBE results, mixed infection, and PrioCHECK FMDV-NS test results in relation to age.

| Age category | n  | Prevalence (95% CI)—LPBE | Mixed infection | Prevalence (95% CI)—PrioCHECK FMDV-NS |
|--------------|----|--------------------------|----------------|----------------------------------------|
| Less than 1 year | 4  | 0                        | 0              | 0                                      |
| 1-2 years    | 37 | 100 (100-100)            | 64.9 (57.6–72.2) | 100 (100-100)                        |
| 3-4 years    | 49 | 93.9 (87.2–100)          | 87.7 (78.1–97.4) | 85.7 (75.9–95.5)                      |
| 5-6 years    | 9  | 100 (100-100)            | 88.9 (87.1–90.7) | 100 (100-100)                        |
| p value      |    | 0.413                    | 0.497          | 0.451                                  |

Table 3: Prevalence of LPBE results, mixed infection, and PrioCHECK FMDV-NS results in buffalo according to sex category.

| Sex      | n  | Prevalence (95% CI)—LPBE | Mixed infection | Prevalence (95% CI)—PrioCHECK FMDV-NS |
|----------|----|--------------------------|----------------|----------------------------------------|
| Female   | 61 | 59 (46.7–71.0)           | 75 (64.1–85.9) | 24.5 (13.7–35.2)                       |
| Male     | 38 | 63.2 (47.9–78.5)         | 71.1 (56.7–65.5) | 28.9 (14.5–43.3)                      |
| p value  |    | 0.861                    | 0.278          | 0.778                                  |

Table 4: LPBE test and PrioCHECK FMDV-NS test cross-tabulation.

| PrioCHECK FMDV-NS test | Negative | Positive | Total |
|------------------------|----------|----------|-------|
| LPBE test              | 4        | 3        | 7     |
| Positive               | 11       | 81       | 92    |
| Total                  | 15       | 84       | 99    |

for FMDV antibodies on PrioCHECK FMDV-NS test. There was a significant difference in prevalence among the different sampling sites (p < 0.05) and this was statistically significant (p value = 0.001). Of the 84 buffaloes that tested positive for FMDV NPS antibodies, 69 were strong positives (>70) and 15 were weak positives (>50 and <70). The prevalence according to age categories was also not statistically different (p value = 0.413) (Table 2). The overall prevalence of females (n = 61) and males (n = 38) on PrioCHECK FMDV-NS test was 86.9% (95% CI = 78.4–95.4) and 81.6% (95% CI = 69.3–93.9), respectively. Further, there was no significant difference in the prevalence of antibodies against SAT serotypes tested in LPBE and against nonstructural proteins (PrioCHECK FMDV-NS test) in relation to age and sex (Table 3).

The cross-tabulation of combined test results for the LPBE SAT serotype ELISA and the PrioCHECK FMDV-NS ELISA among the buffaloes sampled in GMA and NP is shown in Table 4. The results showed a fair agreement between results obtained on PrioCHECK FMDV-NS and LPBE SAT serotypes (kappa = 0.296 at 0.001; McNemar = 0.057).

3.1.3. Virus Isolation and Serotyping by Antigen ELISA in Probang Samples. A total of 49 probang samples (Lundazi, n = 24; and Lower Zambezi, n = 25) were collected, treated, and passaged. Overall cytopathic effects (CPE) suggestive of FMDV replication in primary RM cell cultures were observed in three samples from Lundazi (n = 2) and Lower Zambezi (n = 1). The CPE was characterised by the fast destruction of the cell monolayer from which infected cells were round and seen singly. Complete destruction of the cell sheet was mostly seen within 48 hours of inoculation of the 1st passage or 2nd passage. Samples with CPE were analysed using the antigen ELISA to identify the serotypes. The antigen ELISA analysis showed that two samples from Lundazi were of SAT2 serotypes, and one sample from Lower Zambezi was of the SAT1 serotype.
4. Discussion

The aim of this study was to determine the seroprevalence of the FMD in buffaloes and identify circulating FMDV serotypes in buffalo populations in Zambia. A high prevalence of antibodies against FMDV in buffaloes was observed in all the study areas except in Sioma where only few animals (all calves) were tested. Further, major FMDV SAT types observed to be circulating in buffaloes in Zambia based on the results from LPBE were SAT1, SAT2, and SAT3, while only SAT1 and SAT2 were isolated from probang samples. Our study reveals that FMD could be a problem in study areas. These results corroborate the findings of previous studies which demonstrated high FMDV seroprevalence in buffalo populations in Southern Africa [25, 26]. In our study SAT2 was the most predominant serotype, followed by SAT1 and then SAT3. Overall, all the Game Parks/Game Management Areas had high prevalence of mixed infections, which supports the earlier observation that individual buffaloes may be persistently infected with more than one type of FMDV in the pharyngeal region [27–29]. The LPBE was chosen as it has been used successfully for numerous animal species before, including the African buffalo. While the test shows an almost perfect sensitivity, the specificity in cattle usually is about 95% and similar values were assumed for the African buffalo. However, in cattle up to 18% [30, 31] false positive reactions have been reported. LPBE detects immunoglobulins directed against the capsid or structural proteins of the virus and therefore cannot distinguish antibodies induced by vaccinations using inactivated vaccines from those elicited by infection with live virus [32]. PrioCHECK FMDV-NS detects antibodies against the nonstructural 3ABC protein of FMDV but cannot distinguish between serotypes. However, antibodies to the 3ABC protein are considered to be the most reliable indicators of infection/exposure to FMDV [33, 34]. The specificity of the PrioCHECK FMDV-NS for bovine sera was given as 98.1 percent by [35] while the sensitivity in nonvaccinated, experimentally infected bovines also approached 100 percent. Bronsvooort et al. [36] published sensitivity and specificity estimates of 87.7 percent and 87.3 percent, respectively, for the African buffalo using Bayesian statistics, but their data would be consistent with values closer to those recorded for cattle, in particular if factors like antibody kinetics and sample quality are taken into account.

The study has also revealed that buffaloes within the age of one to two years are most likely to be infected by FMDV as all the buffaloes were positive to FMDV infection at this age. This is in agreement with the findings of previous studies which indicated that, after maternal antibodies wane, the young buffaloes were prone to FMDV infection from the carrier buffaloes [37]. Buffaloes in the age category of 5–6 years were positive for antibodies against FMDV and had mixed infection slightly higher compared to the other categories; this could have been due to the risk that the older the buffaloes are, the more the time they are likely to get infected by different FMDV serotypes is. African buffaloes are efficient maintenance hosts of the SAT type viruses, with an individual animal maintaining the virus up to five years and isolated herds for up to 24 years, although persistence in an individual buffalo is probably not lifelong [37].

Probang samples were collected with the view of isolating FMDV and identifying serotypes in circulation [29, 37, 38]. However, only a small proportion of samples yielded positive results as two, SAT2, and one, SAT1, virus isolates were obtained. This is in line with the report that the excretion of virus by carriers is intermittent [1] and the findings by [10] that reported that the quantity of virus present in the pharynx of carrier animals can vary considerably over time. As part of future studies, it is recommended to obtain more probang samples for virus isolation and also generate nucleotide sequences of these isolates so that the FMDV circulating in these buffaloes can be differentiated to topotypes level to understand their diversity. In addition, the availability of more local FMDV isolates enables the calculation of $r^1$ values required to check and possibly adapt preventive and control measures in endemic or epidemic regions where strategic or general vaccination is required with vaccine containing the FMDV subtypes that are active in the area [29].

In this study, based on LPBE, very few SAT3 seropositive buffalo samples were only seropositive for SAT3 ($n = 5$), while slight proportions were SAT1 seropositive only ($n = 9$) or SAT2 seropositive only ($n = 10$). The majority of samples were positive to more than one serotype, and this raises the issue of to what extent the SAT results are cross-reactions [27]. Virus neutralisation assays using local FMDV isolates would be required to further dissect possible cross-reactivities. In addition, the isolation of a SAT3 FMDV from concurrent probang samples would confirm the presence of this serotype in Zambian buffaloes.

The study showed fair agreement between LPBE test and PrioCHECK FMDV-NS test cross-tabulation results. Lack of substantial or perfect agreement could be attributed to the fact that the kinetics and duration of the antibody response to structural and nonstructural viral proteins differ as does the rate of seroconversion [39].

Antibodies to all the three Southern African Territories (SAT) serotypes were detected in buffaloes in the four study areas (Mosi-oa-tunya, Sichifulo, Lower Zambezi, and Lundazi) where age and sex of the buffalo had no effect in FMDV infection/exposure status. This is in agreement with earlier observations in studies conducted in buffaloes in Sub-Saharan Africa [37]. The exception was Sioma where all the four samples collected from buffaloes in age range of six months to eight months were negative for antibodies against FMDV. Therefore no equivocal statement can be made regarding these results as the apparent absence could be attributed to the small sample size and may be that the young buffaloes had not yet been exposed to FMDV.

There is little published on non-SAT serotypes in buffalo in Zambia. From reported outbreaks in Saharan Africa [37], it appears that the majority of outbreaks in the southern regions are due to SAT serotypes with only sporadic introductions of O and A. Zambia being surrounded by other countries which have reported other serotypes cannot be excluded from harbouring other serotypes apart from SAT serotypes due to the reported outbreaks in Kenya (1994 to 2000), Tanzania
and SADC TADS program for funding this study. They thank the late Director of Veterinary Services Dr. Joseph Mubanga for his assistance with this work. Many thanks are due to Dr. Paul Fandamu, Ms. Mwauseya, Mr. M. Mukubwali, and Mr. M. Simweamba for the technical support. They thank Ms. L. Seoke of BVI for the assistance with laboratory work. They are grateful to the Quality Control Staff of BVI for the good supply of RM monolayer cells.

References

[1] S. Alexandersen, Z. Zhang, and A. I. Donaldson, “Aspects of the persistence of foot-and-mouth disease virus in animals—the carrier problem,” Microbes and Infection, vol. 4, no. 10, pp. 1099–1110, 2002.
[2] F. Brown, “The history of research in foot-and-mouth disease,” Virus Research, vol. 91, no. 1, pp. 3–7, 2003.
[3] N. J. Knowles and A. R. Samuel, “Molecular epidemiology of foot-and-mouth disease virus,” Virus Research, vol. 91, no. 1, pp. 65–80, 2003.
[4] J. B. Brooksby, “Portraits of viruses: foot-and-mouth disease virus,” Intervirology, vol. 18, no. 1-2, pp. 1–23, 1982.
[5] P. Chilonda, J. D. Woodford, B. Ahmadu, K. L. Samui, M. Syakalima, and J. E. D. Mlangwa, “Foot and mouth disease in Zambia: a review of the aetiology and epidemiology and recommendations for possible control,” Revue Scientifique et Technique, vol. 18, no. 3, pp. 585–592, 1999.
[6] E. Overby and G. C. N. Zymbo, “Foot and mouth disease outbreaks in Zambia,” Revue Scientifique et Technique, vol. 2, no. 1, pp. 189–197, 1999.
[7] M. Munyeme, J. B. Muma, H. M. Munangandu, C. Kankya, E. Skjarve, and M. Tryland, “Cattle owners’ awareness of bovine tuberculosis in high and low prevalence settings of the wildlife-livestock interface areas in Zambia,” BMC Veterinary Research, vol. 6, article 21, 2010.
[8] B. W. J. Mahy, “Foot and mouth disease virus,” in Current Topics in Microbiology and Immunology, vol. 288, 2005.
[9] M. G. Mateu, “Antibody recognition of picornaviruses and escape from neutralization: a structural view,” Virus Research, vol. 38, no. 1, pp. 1–24, 1995.
[10] R. P. Kitching, “Clinical variation in foot and mouth disease: cattle,” Revue Scientifique et Technique, vol. 21, no. 3, pp. 499–504, 2002.
[11] Anonymous, Annual Reports of the Department of Veterinary and Livestock Development, Ministry of Agriculture, Livestock and Fisheries, 2005.
[12] Annual Reports of the Department of Veterinary and Livestock Development, Ministry of Agriculture, Livestock and Fisheries, 2008.
[13] Anonymous, Annual Reports of the Department of Veterinary and Livestock Development, Ministry of Agriculture, Livestock and Fisheries, 2006.
[14] Annual Reports of the Department of Veterinary and Livestock Development, Ministry of Agriculture, Livestock and Fisheries, 2007.
[15] Annual Reports of the Department of Veterinary and Livestock Development, Ministry of Agriculture, Livestock and Fisheries, 2009.
[16] Annual Reports of the Department of Veterinary and Livestock Development, Ministry of Agriculture, Livestock and Fisheries, 2010.
[17] Tech. Rep., OIE/FAO FMD Reference Laboratory Network, 2012.

[18] F. Banda, C. J. Kasanga, R. Salu et al., “Investigation of foot-and-mouth disease outbreaks in the Mbalia and Kazungula districts of Zambia,” *Onderstepoort Journal of Veterinary Research*, vol. 81, no. 2, article 721, 2014.

[19] Y. Sinkala, M. Simuunza, D. U. Pfeiffer et al., “Challenges and economic implications in the control of foot and mouth disease in sub-Saharan Africa: Lessons from the Zambian experience,” *Veterinary Medicine International*, vol. 2014, Article ID 373921, 12 pages, 2014.

[20] J. S. S. Dillman, “Foot and mouth disease investigations in game animals (lechwe and buffaloes),” Final Report vol.1, Germany Agency for Technical Cooperation, Government Publishers, Lusaka, Zambia, 1976.

[21] H. K. Mwima, “Wildlife research and management in Zambia with special reference to some protected areas where wild and domestic animals co-exist,” in *The Effects of Enlargement of Domestic Animal Pasture on the Wildlife in Zambia*, Lusaka, Zambia, pp. 305–308, 1995.

[22] OIE, *Manual of Diagnostic Tests and vaccines for Terrestrial Animals*, Office International des Epizooties, Paris, France, 6th edition, 2010.

[23] C. Hamblin, I. T. R. Barnett, and R. S. Hedger, “A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus I. Development and method of ELISA,” *Journal of Immunological Methods*, vol. 93, no. 1, pp. 115–121, 1986.

[24] M. de Diego, E. Brocchi, D. Mackay, and F. de Simone, “Non-structural polyprotein 3ABC of foot-and-mouth disease virus as a diagnostic antigen in ELISA to differentiate infected from vaccinated cattle,” *Archives of Virology*, vol. 142, no. 10, pp. 2021–2033, 1997.

[25] J. J. Esterhuysen, G. R. Thomson, J. R. Flammand, and R. G. Bengis, “Buffalo in the northern Natal game parks show no serological evidence of infection with foot-and-mouth disease virus,” *Onderstepoort Journal of Veterinary Research*, vol. 52, no. 2, pp. 63–66, 1985.

[26] G. R. Thomson, W. Vosloo, and A. D. S. Bastos, “Foot and mouth disease in wildlife,” *Virus Research*, vol. 91, no. 1, pp. 145–161, 2003.

[27] R. S. Hedger, I. T. R. Barnett, D. V. Gradwell, and P. T. Dias, “Serological tests for foot-and-mouth disease in bovine serum samples, problems of interpretation,” *Revue Scientifique et Technique*, vol. 1, pp. 387–393, 1992.

[28] E. C. Anderson, W. J. Doughty, J. Anderson, and R. Paling, “The pathogenesis of foot-and-mouth disease in the African buffalo (*Syncerus caffer*) and the role of this species in the epidemiology of the disease in Kenya,” *Journal of Comparative Pathology*, vol. 89, no. 4, pp. 541–549, 1979.

[29] P. Sutmoller, S. S. Barteling, R. C. Olashcoaga, and K. J. Sumpton, “Control and eradication of foot-and-mouth disease,” *Virus Research*, vol. 91, no. 1, pp. 101–144, 2003.

[30] A. Clavijo, P. Wright, and P. Kitching, “Developments in diagnostic techniques for differentiating infection from vaccination in foot and mouth disease,” *Veterinary Journal*, vol. 167, no. 1, pp. 9–22, 2004.

[31] B. Haas, “Application of the liquid phase blocking sandwich ELISA. Problems encountered in import/export serology and possible solutions,” in *Proceedings of the Session of the Research Group of the European Commission for the Control of Foot and Mouth Disease*, pp. 124–127, EuFMD, Vienna, Austria, 1994.

[32] R. M. Armstrong, S. J. Cox, N. Aggarwal et al., “Detection of antibody to the foot-and-mouth disease virus (FMDV) non-structural polyprotein 3ABC in sheep by ELISA,” *Journal of Virological Methods*, vol. 125, no. 2, pp. 153–163, 2005.

[33] K. J. Sorensen, K. G. Madsen, E. S. Madsen, J. S. Salt, J. Nqindi, and D. K. J. Mackay, “Differentiation of infection from vaccination in foot-and-mouth disease by the detection of antibodies to the non-structural proteins 3D, 3AB and 3ABC in ELISA using antigens expressed in baculovirus,” *Archives of Virology*, vol. 143, no. 8, pp. 1461–1476, 1998.

[34] T. Sun, P. Lu, and X. Wang, “Localization of infection-related epitopes on the non-structural protein 3ABC of foot-and-mouth disease virus and the application of tandem epitopes,” *Journal of Virological Methods*, vol. 119, no. 2, pp. 79–86, 2004.

[35] E. Brocchi, I. E. Bergmann, A. Dekker et al., “Comparative evaluation of six ELISAs for the detection of antibodies to the non-structural proteins of foot-and-mouth disease virus,” *Vaccine*, vol. 24, no. 47–48, pp. 6966–6979, 2006.

[36] B. M. D. C. Bronsvoort, S. Parida, I. Handel et al., “Serological survey for foot-and-mouth disease virus in wildlife in eastern Africa and estimation of test parameters of a nonstructural protein enzyme-linked immunosorbent assay for buffalo,” *Clinical and Vaccine Immunology*, vol. 15, no. 6, pp. 1003–1011, 2008.

[37] G. R. Thomson, A. D. S. Bastos, O. Sangare, S. K. Hargreaves, and G. R. Thomson, “Review of the status and control of foot and mouth disease in sub-Saharan Africa,” *Scientific and Technical Review*, vol. 21, no. 3, pp. 437–449, 2002.

[38] M. Rémond, C. Kaiser, and F. Lebretin, “Diagnosis and screening of foot-and-mouth disease,” *Comparative Immunology, Microbiology and Infectious Diseases*, vol. 25, no. 5–6, pp. 309–320, 2002.

[39] B. M. D. Bronsvoort, N. Toft, I. E. Bergmann et al., “Evaluation of three 3ABC ELISAs for foot-and-mouth disease non-structural antibodies using latent class analysis,” *BMC Veterinary Research*, vol. 2, article 30, 2006.

[40] G. R. Thomson and A. D. S. Bastos, “Foot and mouth disease,” in *Infectious Diseases of Livestock*, J. A. W. Coetzer and R. C. Tustin, Eds., pp. 1324–1365, Oxford University Press, Cape Town, South Africa, 2nd edition, 2004.

[41] P. S. Dawe, F. O. Flanagan, R. L. Madekurozwa et al., “Natural transmission of foot-and-mouth disease virus from African buffalo (*Syncerus caffer*) to cattle in a wildlife area of Zimbabwe,” *Veterinary Record*, vol. 134, no. 10, pp. 230–232, 1994.

[42] P. S. Dawe, K. Sorensen, N. P. Ferris, I. T. Barnett, R. M. Armstrong, and N. J. Knowles, “Experimental transmission of foot-and-mouth disease virus from carrier African buffalo (*Syncerus caffer*) to cattle in Zimbabwe,” *Veterinary Record*, vol. 134, no. 9, pp. 211–215, 1994.

[43] A. D. S. Bastos, D. T. Haydon, O. Sangaré, C. I. Boshoff, J. L. Edrich, and G. R. Thomson, “The implications of virus diversity within the SAT2 serotype for control of foot-and-mouth disease in sub-Saharan Africa,” *Journal of General Virology*, vol. 84, no. 6, pp. 1595–1606, 2003.

[44] R. G. Bengis, G. R. Thomson, R. S. Hedger, V. De Vos, and A. Pini, “Foot-and-mouth disease and the African buffalo (*Syncerus caffer*). 1. Carriers as a source of infection for cattle,” *The Onderstepoort Journal of Veterinary Research*, vol. 53, no. 2, pp. 69–73, 1986.

[45] J. B. Condy and R. S. Hedger, “The survival of foot and mouth disease virus in African buffalo with non-transference of infection to domestic cattle,” *Research in Veterinary Science*, vol. 16, no. 2, pp. 182–185, 1974.
[46] M. D. Gainaru, G. R. Thomson, R. G. Bengis, J. J. Esterhuysen, W. Bruce, and A. Pini, "Foot-and-mouth disease and the African buffalo (Syncerus caffer). II. Virus excretion and transmission during acute infection," *The Onderstepoort Journal of Veterinary Research*, vol. 53, no. 2, pp. 75–85, 1986.

[47] G. R. Thomson, "The role of carrier animals in the transmission of foot and mouth diseases," OIE Comprehensive Reports on Technical Items Presented to the International Committee or to Regional Commissions, 1996.